-
公开(公告)号：EP4370540A2
公开(公告)日：2024-05-22
申请号：EP22751234.0
申请日：2022-07-11
发明人： COUKOS, George , HARARI, Alexandre , BOBISSE, Sara , ARNAUD, Marion , BASSANI-STERNBERG, Michal
IPC分类号： C07K14/725 , A61P35/00 , C07K14/82 , A61K38/17
CPC分类号： C07K14/7051 , A61P35/00 , C07K14/82 , A61K38/00 , A61K2239/5720230501 , A61K39/464401 , A61K2239/3120230501 , A61K2239/3820230501 , A61K39/4611 , A61K39/4632
-
公开(公告)号：EP3303394B1
公开(公告)日：2020-04-08
申请号：EP16728509.7
申请日：2016-05-27
申请人： Agenus Inc. , Ludwig Institute for Cancer Research Ltd , Memorial Sloan Kettering Cancer Center
发明人： van DIJK, Marc , MUNDT, Cornelia, Anne , RITTER, Gerd , SCHAER, David , WOLCHOK, Jedd, David , MERGHOUB, Taha , SAVITSKY, David, Adam , FINDEIS, Mark, Arthur , WILSON, Nicholas, Stuart
IPC分类号： C07K16/28
-
公开(公告)号：EP2785683B1
公开(公告)日：2020-02-05
申请号：EP12798262.7
申请日：2012-11-30
发明人： CERUNDOLO, Vincenzo , BESRA, Gurdyal , LIAM, Cox
IPC分类号： C07C233/18 , A61K45/06
-
公开(公告)号：EP3551225A1
公开(公告)日：2019-10-16
申请号：EP17818020.4
申请日：2017-12-07
申请人： Agenus Inc. , Ludwig Institute for Cancer Research Ltd , Memorial Sloan Kettering Cancer Center
发明人： VAN DIJK, Marc , MUNDT, Cornelia Anne , RITTER, Gerd , SCHAER, David , WOLCHOK, Jedd David , MERGHOUB, Taha , WILSON, Nicholas Stuart , SAVITSKY, David Adam , FINDEIS, Mark Arthur , ZAPPASODI, Roberta , HOLMGAARD, Rikke Bæk , CUILLEROT, Jean-Marie , PROSCURSHIM, Igor , SHEBANOVA, Olga
IPC分类号： A61K39/395 , C07K16/28
-
公开(公告)号：EP2820041B1
公开(公告)日：2017-06-14
申请号：EP13710227.3
申请日：2013-03-01
申请人： Ludwig Institute For Cancer Research Ltd. , Chancellors, Masters & Scholars of the University of Oxford
IPC分类号： C07K16/00 , C07K14/00 , G01N33/574 , G06F19/00 , A61P35/00
CPC分类号： G01N33/57496 , A61K2039/505 , C07K14/4703 , C07K14/4746 , C07K16/18 , C07K16/30 , C07K16/44 , C07K2317/34 , C07K2317/76 , G01N2333/4704 , G01N2333/4748 , G01N2440/14 , G01N2800/56 , G06F19/00 , G16H50/30
摘要： Described herein are methods of evaluating metastatic potential of a cancer based on the phosphorylation state and/or intracellular localization of iASPP. Therapeutic regimens designed based on the results of the diagnostic methods are also provided.
摘要翻译： 本文描述了基于iASPP的磷酸化状态和/或细胞内定位评估癌症的转移潜能的方法。 还提供了基于诊断方法结果设计的治疗方案。
-
公开(公告)号：EP3176270A1
公开(公告)日：2017-06-07
申请号：EP16203301.3
申请日：2008-05-23
IPC分类号： C12Q1/68
摘要： The invention relates to prognostic markers and prognostic signatures, and compositions and methods for determining the prognosis of cancer in a patient, particularly for melanoma. Specifically, the invention relates to the use of genetic and protein markers for the prediction of the risk of progression of a cancer, such as melanoma, based on markers and signatures of markers. In various aspects, the invention provides methods, compositions, kits, and devices based on prognostic cancer markers, specifically melanoma prognostic markers, to aid in the prognosis and treatment of cancer.
摘要翻译： 本发明涉及预后标志物和预后特征，以及用于确定患者中癌症预后的组合物和方法，特别是用于黑素瘤。 具体而言，本发明涉及基于标志物和标志物的标志物和基因标志物，用于预测癌症（例如黑素瘤）发展风险的遗传和蛋白质标志物的用途。 在各个方面，本发明提供基于预后癌症标志物，特别是黑素瘤预后标志物的方法，组合物，试剂盒和装置，以辅助癌症的预后和治疗。
-
7.发明授权EPHA3 ANTIBODIES FOR THE TREATMENT OF SOLID TUMORS 有权EP HA3-ANTIKÖRPERZUR BEHANDLUNG VON SOLIDEN TUMOREN
公开(公告)号：EP2136838B1
公开(公告)日：2017-03-08
申请号：EP08726647.4
申请日：2008-03-10
申请人： KaloBios Pharmaceuticals, Inc. , Monash University , Ludwig Institute for Cancer Research Limited
发明人： LACKMANN, Martin , SCOTT, Andrew Mark , BEBBINGTON, Christopher R. , YARRANTON, Geoffrey T. , TO, Catherine , MURONE, Carmelina
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： C07K16/2866 , A61K47/6803 , A61K47/6849 , A61K51/1033 , A61K2039/505 , C07K2317/24 , C07K2317/73
-
8.发明授权TRUNCATED VARIANT OF THE MAMMALIAN TARGET FOR RAPAMYCIN (MTOR) PROTEIN 有权GEKÜRZTEVARIANTE DES PROTEINS DESSÄUGETIER-TARGETSFÜRRAPAMYCIN（MTAM的RAPAMYCIN MAMMALIAN TARGET）
公开(公告)号：EP2139914B1
公开(公告)日：2017-03-01
申请号：EP08737164.7
申请日：2008-05-01
IPC分类号： C07K14/705 , C12Q1/48 , C12N9/12 , C07K14/47
CPC分类号： C12N9/12 , C07K14/4702 , C07K14/705 , C07K16/40 , C07K2317/24 , C07K2317/76 , C12P21/02 , C12Q1/485 , C12Q1/6876 , C12Q2600/156 , C12Q2600/158 , C12Y207/11001 , G01N33/5008 , G01N2440/14
摘要： The invention relates to mTORbeta, a splice form of mTOR, nucleic acids encoding mTOR beta, and antibodies against mTOR beta. The invention also relates to methods of producing mTOR beta and methods of screening for an agent that modulates mTOR beta expression and/or activity. The invention further relates to a method of treating a disease associated with aberrant expression of mTOR beta by administration of an agent that alters mTOR activity and/or expression.
摘要翻译： 本发明涉及mTORbeta，mTOR的剪接形式，编码mTORβ的核酸和针对mTORβ的抗体。 本发明还涉及产生mTORβ的方法和筛选调节mTORβ表达和/或活性的试剂的方法。 本发明还涉及通过施用改变mTOR活性和/或表达的试剂来治疗与mTORβ异常表达相关的疾病的方法。
-
公开(公告)号：EP2158332B1
公开(公告)日：2017-01-18
申请号：EP08766967.7
申请日：2008-05-23
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/158 , C12Q2600/16 , G06F19/00 , G16H50/30
摘要： The invention relates to prognostic markers and prognostic signatures, and compositions and methods for determining the prognosis of cancer in a patient, particularly for melanoma. Specifically, the invention relates to the use of genetic and protein markers for the prediction of the risk of progression of a cancer, such as melanoma, based on markers and signatures of markers. In various aspects, the invention provides methods, compositions, kits, and devices based on prognostic cancer markers, specifically melanoma prognostic markers, to aid in the prognosis and treatment of cancer.
-
公开(公告)号：EP3027650A1
公开(公告)日：2016-06-08
申请号：EP14748185.7
申请日：2014-08-01
发明人： LUCAS, Sophie , COULIE, Pierre , CUENDE VILLASUR, Julia , DUMOUTIER, Laure , RENAULD, Jean-Christophe , VAN DE WONING, Sebastian , SAUNDERS, Michael , DE HAARD, Hans , DE BOECK, Gitte
CPC分类号： C07K16/2875 , A61K2039/505 , C07K16/28 , C07K16/30 , C07K2317/22 , C07K2317/24 , C07K2317/31 , C07K2317/32 , C07K2317/41 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/569 , C07K2317/622 , C07K2317/624 , C07K2317/626 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to an antibody binding to the transmembrane protein ‘glycoprotein A repetitions predominant’ (GARP) in the presence of TGF-β and uses thereof.
摘要翻译： 本发明涉及在TGF-β存在下与跨膜蛋白“重复占优势”（GARP）结合的抗体及其用途。
-
-
-
-
-
-
-
-
-
搜索结果
559 条记录 (耗时 0.045 秒)
